

REFERENCES

1. Walker, R. A., Pryer, N. K., and Salmon, E. D. Dilution of individual microtubules observed in real time in vitro: evidence that cap size is small and independent of elongation rate. *J Cell Biol*, *114*: 73-81, 1991.
2. Jordan, M. A. and Wilson, L. The use and action of drugs in analyzing mitosis. *Methods Cell Biol*, *61*: 267-295, 1999.
3. Joshi, H. C. Microtubule dynamics in living cells. *Curr Opin Cell Biol*, *10*: 35-44, 1998.
4. Saxton, W. M., Stemple, D. L., Leslie, R. J., Salmon, E. D., Zavortink, M., and McIntosh, J. R. Tubulin dynamics in cultured mammalian cells. *J Cell Biol*, *99*: 2175-2186, 1984.
5. Schulze, E. and Kirschner, M. Microtubule dynamics in interphase cells. *J Cell Biol*, *102*: 1020-1031, 1986.
6. Pepperkok, R., Bre, M. H., Davoust, J., and Kreis, T. E. Microtubules are stabilized in confluent epithelial cells but not in fibroblasts. *J Cell Biol*, *111*: 3003-3012, 1990.
7. Belmont, L. D., Hyman, A. A., Sawin, K. E., and Mitchison, T. J. Real-time visualization of cell cycle-dependent changes in microtubule dynamics in cytoplasmic extracts. *Cell*, *62*: 579-589, 1990.
8. Luduena, R. F. Multiple forms of tubulin: different gene products and covalent modifications. *Int Rev Cytol*, *178*: 207-275, 1998.
9. Orr, G. A., Verdier-Pinard, P., McDaid, H., and Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules. *Oncogene*, *22*: 7280-7295, 2003.
10. Nicoletti, M. I., Valoti, G., Giannakakou, P., Zhan, Z., Kim, J. H., Lucchini, V., Landoni, F., Mayo, J. G., Giavazzi, R., and Fojo, T. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. *Clin Cancer Res*, *7*: 2912-2922, 2001.
11. Dutcher, S. K. and Trabuco, E. C. The UNI3 gene is required for assembly of basal bodies of *Chlamydomonas* and encodes delta-tubulin, a new member of the tubulin superfamily. *Mol Biol Cell*, *9*: 1293-1308, 1998.
12. Vaughan, S., Attwood, T., Navarro, M., Scott, V., McKean, P., and Gull, K. New tubulins in protozoal parasites. *Curr Biol*, *10*: R258-259, 2000.
13. Dutcher, S. K. The tubulin fraternity: alpha to eta. *Curr Opin Cell Biol*, *13*: 49-54, 2001.
14. Oakley, B. R. An abundance of tubulins. *Trends Cell Biol*, *10*: 537-542, 2000.
15. Oakley, C. E. and Oakley, B. R. Identification of gamma-tubulin, a new member of the tubulin superfamily encoded by mipA gene of *Aspergillus nidulans*. *Nature*, *338*: 662-664, 1989.
16. Westermann, S. and Weber, K. Post-translational modifications regulate microtubule function. *Nat Rev Mol Cell Biol*, *4*: 938-947, 2003.

17. Piperno, G., LeDizet, M., and Chang, X. J. Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. *J Cell Biol*, *104*: 289-302, 1987.
18. Robson, S. J. and Burgoyne, R. D. Differential localisation of tyrosinated, detyrosinated, and acetylated alpha-tubulins in neurites and growth cones of dorsal root ganglion neurons. *Cell Motil Cytoskeleton*, *12*: 273-282, 1989.
19. Cambray-Deakin, M. A., Robson, S. J., and Burgoyne, R. D. Colocalisation of acetylated microtubules, glial filaments, and mitochondria in astrocytes in vitro. *Cell Motil Cytoskeleton*, *10*: 438-449, 1988.
20. Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., and Matthias, P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. *Embo J*, *22*: 1168-1179, 2003.
21. Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X. F., and Yao, T. P. HDAC6 is a microtubule-associated deacetylase. *Nature*, *417*: 455-458, 2002.
22. McIntosh, J. R. and Euteneuer, U. Tubulin hooks as probes for microtubule polarity: an analysis of the method and an evaluation of data on microtubule polarity in the mitotic spindle. *J Cell Biol*, *98*: 525-533, 1984.
23. Inoue, S. and Salmon, E. D. Force generation by microtubule assembly/disassembly in mitosis and related movements. *Mol Biol Cell*, *6*: 1619-1640, 1995.
24. Sawin, K. E., Mitchison, T. J., and Wordeman, L. G. Evidence for kinesin-related proteins in the mitotic apparatus using peptide antibodies. *J Cell Sci*, *101 (Pt 2)*: 303-313, 1992.
25. Sawin, K. E., LeGuellec, K., Philippe, M., and Mitchison, T. J. Mitotic spindle organization by a plus-end-directed microtubule motor. *Nature*, *359*: 540-543, 1992.
26. McIntosh, J. R. Structural and mechanical control of mitotic progression. *Cold Spring Harb Symp Quant Biol*, *56*: 613-619, 1991.
27. McIntosh, J. R. and Hering, G. E. Spindle fiber action and chromosome movement. *Annu Rev Cell Biol*, *7*: 403-426, 1991.
28. McIntosh, J. R. and Pfarr, C. M. Mitotic motors. *J Cell Biol*, *115*: 577-585, 1991.
29. Rieder, C. L., Cole, R. W., Khodjakov, A., and Sluder, G. The checkpoint delaying anaphase in response to chromosome monoorientation is mediated by an inhibitory signal produced by unattached kinetochores. *J Cell Biol*, *130*: 941-948, 1995.
30. Gorbsky, G. J. and Ricketts, W. A. Differential expression of a phosphoepitope at the kinetochores of moving chromosomes. *J Cell Biol*, *122*: 1311-1321, 1993.
31. Wittmann, T., Hyman, A., and Desai, A. The spindle: a dynamic assembly of microtubules and motors. *Nat Cell Biol*, *3*: E28-34, 2001.
32. Gundersen, G. G. and Cook, T. A. Microtubules and signal transduction. *Curr Opin Cell Biol*, *11*: 81-94., 1999.
33. Mallik, R., Carter, B. C., Lex, S. A., King, S. J., and Gross, S. P. Cytoplasmic dynein functions as a gear in response to load. *Nature*, *427*: 649-652, 2004.
34. Goodson, H. V., Skube, S. B., Stalder, R., Valetti, C., Kreis, T. E., Morrison, E. E., and Schroer, T. A. CLIP-170 interacts with dynactin complex and the APC-

- binding protein EB1 by different mechanisms. *Cell Motil Cytoskeleton*, *55*: 156-173, 2003.
35. Valetti, C., Wetzell, D. M., Schrader, M., Hasbani, M. J., Gill, S. R., Kreis, T. E., and Schroer, T. A. Role of dynactin in endocytic traffic: effects of dynamitin overexpression and colocalization with CLIP-170. *Mol Biol Cell*, *10*: 4107-4120, 1999.
 36. Suomalainen, M., Nakano, M. Y., Keller, S., Boucke, K., Stidwill, R. P., and Greber, U. F. Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. *J Cell Biol*, *144*: 657-672, 1999.
 37. Eckley, D. M., Gill, S. R., Melkonian, K. A., Bingham, J. B., Goodson, H. V., Heuser, J. E., and Schroer, T. A. Analysis of dynactin subcomplexes reveals a novel actin-related protein associated with the arp1 minifilament pointed end. *J Cell Biol*, *147*: 307-320, 1999.
 38. Quintyne, N. J., Gill, S. R., Eckley, D. M., Crego, C. L., Compton, D. A., and Schroer, T. A. Dynactin is required for microtubule anchoring at centrosomes. *J Cell Biol*, *147*: 321-334, 1999.
 39. Allan, V. Motor proteins: a dynamic duo. *Curr Biol*, *6*: 630-633, 1996.
 40. Holleran, E. A., Karki, S., and Holzbaur, E. L. The role of the dynactin complex in intracellular motility. *Int Rev Cytol*, *182*: 69-109, 1998.
 41. King, S. J. and Schroer, T. A. Dynactin increases the processivity of the cytoplasmic dynein motor. *Nat Cell Biol*, *2*: 20-24, 2000.
 42. Schafer, D. A., Gill, S. R., Cooper, J. A., Heuser, J. E., and Schroer, T. A. Ultrastructural analysis of the dynactin complex: an actin-related protein is a component of a filament that resembles F-actin. *J Cell Biol*, *126*: 403-412, 1994.
 43. Echeverri, C. J., Paschal, B. M., Vaughan, K. T., and Vallee, R. B. Molecular characterization of the 50-kD subunit of dynactin reveals function for the complex in chromosome alignment and spindle organization during mitosis. *J Cell Biol*, *132*: 617-633, 1996.
 44. Goodson, H. V., Valetti, C., and Kreis, T. E. Motors and membrane traffic. *Curr Opin Cell Biol*, *9*: 18-28, 1997.
 45. Burkhardt, J. K., Echeverri, C. J., Nilsson, T., and Vallee, R. B. Overexpression of the dynamitin (p50) subunit of the dynactin complex disrupts dynein-dependent maintenance of membrane organelle distribution. *J Cell Biol*, *139*: 469-484, 1997.
 46. Kikkawa, M., Sablin, E. P., Okada, Y., Yajima, H., Fletterick, R. J., and Hirokawa, N. Switch-based mechanism of kinesin motors. *Nature*, *411*: 439-445, 2001.
 47. Heggeness, M. H., Simon, M., and Singer, S. J. Association of mitochondria with microtubules in cultured cells. *Proc Natl Acad Sci U S A*, *75*: 3863-3866, 1978.
 48. Nangaku, M., Sato-Yoshitake, R., Okada, Y., Noda, Y., Takemura, R., Yamazaki, H., and Hirokawa, N. KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria. *Cell*, *79*: 1209-1220, 1994.
 49. Tanaka, Y., Kanai, Y., Okada, Y., Nonaka, S., Takeda, S., Harada, A., and Hirokawa, N. Targeted disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal perinuclear clustering of mitochondria. *Cell*, *93*: 1147-1158, 1998.

50. Terasaki, M. and Reese, T. S. Interactions among endoplasmic reticulum, microtubules, and retrograde movements of the cell surface. *Cell Motil Cytoskeleton*, *29*: 291-300, 1994.
51. Thyberg, J. and Moskalewski, S. Microtubules and the organization of the Golgi complex. *Exp Cell Res*, *159*: 1-16, 1985.
52. Wiemer, E. A., Wenzel, T., Deerinck, T. J., Ellisman, M. H., and Subramani, S. Visualization of the peroxisomal compartment in living mammalian cells: dynamic behavior and association with microtubules. *J Cell Biol*, *136*: 71-80, 1997.
53. Collot, M., Louvard, D., and Singer, S. J. Lysosomes are associated with microtubules and not with intermediate filaments in cultured fibroblasts. *Proc Natl Acad Sci U S A*, *81*: 788-792, 1984.
54. Ebnet, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. *J Cell Biol*, *143*: 777-794, 1998.
55. Gurland, G. and Gundersen, G. G. Stable, detyrosinated microtubules function to localize vimentin intermediate filaments in fibroblasts. *J Cell Biol*, *131*: 1275-1290, 1995.
56. Jordan, M. A. and Wilson, L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. *Curr Opin Cell Biol*, *10*: 123-130., 1998.
57. Giannakakou, P., Sackett, D. L., Ward, Y., Webster, K. R., Blagosklonny, M. V., and Fojo, T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. *Nat Cell Biol*, *2*: 709-717., 2000.
58. Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., and Pratt, W. B. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. *J Biol Chem*, *279*: 22483-22489, 2004.
59. Galigniana, M. D., Harrell, J. M., Murphy, P. J., Chinkers, M., Radanyi, C., Renoir, J. M., Zhang, M., and Pratt, W. B. Binding of hsp90-associated immunophilins to cytoplasmic dynein: direct binding and in vivo evidence that the peptidylprolyl isomerase domain is a dynein interaction domain. *Biochemistry*, *41*: 13602-13610, 2002.
60. Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., and Krek, W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. *Nat Cell Biol*, *5*: 64-70, 2003.
61. Mabeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., and Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. *Cancer Cell*, *3*: 363-375, 2003.
62. Bearer, E. L. and Satpute-Krishnan, P. The role of the cytoskeleton in the life cycle of viruses and intracellular bacteria: tracks, motors, and polymerization machines. *Curr Drug Targets Infect Disord*, *2*: 247-264, 2002.
63. Jansen, R. P. mRNA localization: message on the move. *Nat Rev Mol Cell Biol*, *2*: 247-256, 2001.
64. Pokrywka, N. J. and Stephenson, E. C. Microtubules mediate the localization of bicoid RNA during *Drosophila* oogenesis. *Development*, *113*: 55-66, 1991.

65. Yisraeli, J. K., Sokol, S., and Melton, D. A. A two-step model for the localization of maternal mRNA in *Xenopus* oocytes: involvement of microtubules and microfilaments in the translocation and anchoring of Vg1 mRNA. *Development*, *108*: 289-298, 1990.
66. Hesketh, J. E. and Pryme, I. F. Interaction between mRNA, ribosomes and the cytoskeleton. *Biochem J*, *277 (Pt 1)*: 1-10, 1991.
67. Hovland, R., Campbell, G., Pryme, I., and Hesketh, J. The mRNAs for cyclin A, c-myc and ribosomal proteins L4 and S6 are associated with cytoskeletal-bound polysomes in HepG2 cells. *Biochem J*, *310 (Pt 1)*: 193-196, 1995.
68. Hovland, R., Hesketh, J. E., and Pryme, I. F. The compartmentalization of protein synthesis: importance of cytoskeleton and role in mRNA targeting. *Int J Biochem Cell Biol*, *28*: 1089-1105, 1996.
69. Kwon, S., Barbarese, E., and Carson, J. H. The cis-acting RNA trafficking signal from myelin basic protein mRNA and its cognate trans-acting ligand hnRNP A2 enhance cap-dependent translation. *J Cell Biol*, *147*: 247-256, 1999.
70. Huang, Y. S., Carson, J. H., Barbarese, E., and Richter, J. D. Facilitation of dendritic mRNA transport by CPEB. *Genes Dev*, *17*: 638-653, 2003.
71. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. *Curr Med Chem Anti-Canc Agents.*, *2*: 1-17, 2002.
72. Rowinsky, E. K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. *Annu Rev Med*, *48*: 353-374, 1997.
73. Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., and McPhail, A. T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from *Taxus brevifolia*. *J Am Chem Soc*, *93*: 2325-2327, 1971.
74. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. *Nature*, *277*: 665-667, 1979.
75. Rao, S., Horwitz, S. B., and Ringel, I. Direct photoaffinity labeling of tubulin with taxol. *J Natl Cancer Inst*, *84*: 785-788., 1992.
76. Rao, S., Krauss, N. E., Heering, J. M., Swindell, C. S., Ringel, I., Orr, G. A., and Horwitz, S. B. 3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. *J Biol Chem*, *269*: 3132-3134., 1994.
77. Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G., and Horwitz, S. B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. *J Biol Chem*, *270*: 20235-20238., 1995.
78. Rao, S., He, L., Chakravarty, S., Ojima, I., Orr, G. A., and Horwitz, S. B. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. *J Biol Chem*, *274*: 37990-37994., 1999.
79. Nogales, E., Wolf, S. G., and Downing, K. H. Structure of the alpha beta tubulin dimer by electron crystallography. *Nature*, *391*: 199-203., 1998.
80. Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E., and Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. *Cancer Res*, *55*: 2325-2333., 1995.

81. ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., and Day, B. W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. *Biochemistry*, 35: 243-250, 1996.
82. Long, B. H., Carboni, J. M., Wasserman, A. J., Cornell, L. A., Casazza, A. M., Jensen, P. R., Lindel, T., Fenical, W., and Fairchild, C. R. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). *Cancer Res*, 58: 1111-1115., 1998.
83. Bai, R. L., Lin, C. M., Nguyen, N. Y., Liu, T. Y., and Hamel, E. Identification of the cysteine residue of beta-tubulin alkylated by the antimitotic agent 2,4-dichlorobenzyl thiocyanate, facilitated by separation of the protein subunits of tubulin by hydrophobic column chromatography. *Biochemistry*, 28: 5606-5612, 1989.
84. Shan, B., Medina, J. C., Santha, E., Frankmoelle, W. P., Chou, T. C., Learned, R. M., Narbut, M. R., Stott, D., Wu, P., Jaen, J. C., Rosen, T., Timmermans, P. B., and Beckmann, H. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. *Proc Natl Acad Sci U S A*, 96: 5686-5691, 1999.
85. Pettit, G. R., Singh, S. B., Schmidt, J. M., Niven, M. L., Hamel, E., and Lin, C. M. Isolation, structure, synthesis, and antimitotic properties of combretastatins B-3 and B-4 from *Combretum cafferum*. *J Nat Prod*, 51: 517-527, 1988.
86. Blokhin, A. V., Yoo, H. D., Gerald, R. S., Nagle, D. G., Gerwick, W. H., and Hamel, E. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues. *Mol Pharmacol*, 48: 523-531, 1995.
87. D'Amato, R. J., Lin, C. M., Flynn, E., Folkman, J., and Hamel, E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. *Proc Natl Acad Sci U S A*, 91: 3964-3968., 1994.
88. Wilson, L. Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. *Biochemistry*, 9: 4999-5007, 1970.
89. Lin, C. M., Hamel, E., and Wolpert-DeFilippes, M. K. Binding of maytansine to tubulin: competition with other mitotic inhibitors. *Res Commun Chem Pathol Pharmacol*, 31: 443-451, 1981.
90. Bai, R. L., Pettit, G. R., and Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. *J Biol Chem*, 265: 17141-17149., 1990.
91. Nunes, M., Kaplan, J., Loganzo, F., Zask, A., Ayril-Kaloustian, S., and Greenberger, L. M. Two photoaffinity analogs of HTI-286, a synthetic analog of hemisasterlin, interact with alpha-tubulin. *Eur. J. Cancer*, 38, 2002.
92. Bai, R., Durso, N. A., Sackett, D. L., and Hamel, E. Interactions of the sponge-derived antimitotic tripeptide hemisasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. *Biochemistry*, 38: 14302-14310, 1999.
93. Hamel, E. Interactions of antimitotic peptides and depsipeptides with tubulin. *Biopolymers*, 66: 142-160, 2002.

94. Pryor, D., O'Brate, A., Bilcer, G., Díaz, J. F., Wang, W., Wang, Y., Kabaki, M., M.K., J., Andreu, J. M., Ghosh, A. K., Giannakakou, P., and Hamel, E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. *Biochemistry, In press*, 2002.
95. Pineda, O., Farras, J., Maccari, L., Manetti, F., Botta, M., and Vilarrasa, J. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. *Bioorg Med Chem Lett*, *14*: 4825-4829, 2004.
96. Weisenberg, R. C., Borisy, G. G., and Taylor, E. W. The colchicine-binding protein of mammalian brain and its relation to microtubules. *Biochemistry*, *7*: 4466-4479, 1968.
97. Borisy, G. G. and Taylor, E. W. The mechanism of action of colchicine. Colchicine binding to sea urchin eggs and the mitotic apparatus. *J Cell Biol*, *34*: 535-548, 1967.
98. Hamel, E. and Lin, C. M. Interactions of combretastatin, a new plant-derived antimetabolic agent, with tubulin. *Biochem Pharmacol*, *32*: 3864-3867, 1983.
99. Cirila, A. and Mann, J. Combretastatins: from natural products to drug discovery. *Nat Prod Rep*, *20*: 558-564, 2003.
100. Tozer, G. M., Prise, V. E., Wilson, J., Cemazar, M., Shan, S., Dewhurst, M. W., Barber, P. R., Vojnovic, B., and Chaplin, D. J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. *Cancer Res*, *61*: 6413-6422., 2001.
101. Pribluda, V. S., Gubish, E. R., Jr., Lavalley, T. M., Treston, A., Swartz, G. M., and Green, S. J. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. *Cancer Metastasis Rev*, *19*: 173-179, 2000.
102. Duflos, A., Kruczynski, A., and Barret, J. M. Novel aspects of natural and modified vinca alkaloids. *Curr Med Chem Anti-Canc Agents*, *2*: 55-70, 2002.
103. Jimenez-Barbero, J., Amat-Guerri, F., and Snyder, J. P. The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. *Curr Med Chem Anti-Canc Agents*, *2*: 91-122, 2002.
104. McKellar, Q. A. and Scott, E. W. The benzimidazole anthelmintic agents--a review. *J Vet Pharmacol Ther*, *13*: 223-247, 1990.
105. Ben-Chetrit, E. and Levy, M. Colchicine: 1998 update. *Semin Arthritis Rheum*, *28*: 48-59, 1998.
106. Borstad, G. C., Bryant, L. R., Abel, M. P., Scroggie, D. A., Harris, M. D., and Alloway, J. A. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. *J Rheumatol*, *31*: 2429-2432, 2004.
107. Rowinsky, E. K. On pushing the outer edge of the outer edge of paclitaxel's dosing envelope. *Clin Cancer Res*, *5*: 481-486., 1999.
108. Ling, V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. *Cancer*, *69*: 2603-2609, 1992.
109. Horwitz, S. B., Cohen, D., Rao, S., Ringel, I., Shen, H. J., and Yang, C. P. Taxol: mechanisms of action and resistance. *J Natl Cancer Inst Monogr* 55-61, 1993.

110. Jaffrezou, J. P., Dumontet, C., Derry, W. B., Duran, G., Chen, G., Tsuchiya, E., Wilson, L., Jordan, M. A., and Sikic, B. I. Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. *Oncol Res*, 7: 517-527, 1995.
111. Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., and Horwitz, S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isoforms. *J Clin Invest*, 100: 1282-1293, 1997.
112. Haber, M., Burkhart, C. A., Regl, D. L., Madafoglio, J., Norris, M. D., and Horwitz, S. B. Altered expression of M beta 2, the class II beta-tubulin isoform, in a murine J774.2 cell line with a high level of taxol resistance. *J Biol Chem*, 270: 31269-31275, 1995.
113. Goncalves, A., Braguer, D., Kamath, K., Martello, L., Briand, C., Horwitz, S., Wilson, L., and Jordan, M. A. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. *Proc Natl Acad Sci U S A*, 98: 11737-11742., 2001.
114. Kamath, K., Wilson, L., Cabral, F., and Jordan, M. A. beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. *J Biol Chem*, 280: 12902-12907, 2005.
115. Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T., and Poruchynsky, M. S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. *J Biol Chem*, 272: 17118-17125., 1997.
116. Gonzalez-Garay, M. L., Chang, L., Blade, K., Menick, D. R., and Cabral, F. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. *J Biol Chem*, 274: 23875-23882, 1999.
117. Hari, M., Loganzo, F., Annable, T., Tan, X., Musto, S., Morilla, D. B., Nettles, J. H., Snyder, J. P., and Greenberger, L. M. Paclitaxel resistant cells have a mutation in the paclitaxel binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Submitted.
118. Wiesen, K. M., Xia, S., and Horwitz, S. B. Exogenous class I beta-tubulin sensitizes Taxol-resistant MDA cells. *Proc. Amer. Assoc. Cancer Res.*, 43: 788, 2002.
119. Monzo, M., Rosell, R., Sanchez, J. J., Lee, J. S., O'Brate, A., Gonzalez-Larriba, J. L., Alberola, V., Lorenzo, J. C., Nunez, L., Ro, J. Y., and Martin, C. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. *J Clin Oncol*, 17: 1786-1793, 1999.
120. Davidse, L. C. and Flach, W. Differential binding of methyl benzimidazol-2-yl carbamate to fungal tubulin as a mechanism of resistance to this antimitotic agent in mutant strains of *Aspergillus nidulans*. *J Cell Biol*, 72: 174-193, 1977.
121. Ling, V., Aubin, J. E., Chase, A., and Sarangi, F. Mutants of Chinese hamster ovary (CHO) cells with altered colcemid-binding affinity. *Cell*, 18: 423-430, 1979.
122. Cabral, F., Sobel, M. E., and Gottesman, M. M. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin. *Cell*, 20: 29-36, 1980.

123. Yamamoto, M. Genetic analysis of resistant mutants to antimitotic benzimidazole compounds in *Schizosaccharomyces pombe*. *Mol Gen Genet*, *180*: 231-234, 1980.
124. Burland, T. G., Schedl, T., Gull, K., and Dove, W. F. Genetic analysis of resistance to benzimidazoles in *Physarum*: differential expression of beta-tubulin genes. *Genetics*, *108*: 123-141, 1984.
125. Orbach, M. J., Porro, E. B., and Yanofsky, C. Cloning and characterization of the gene for beta-tubulin from a benomyl-resistant mutant of *Neurospora crassa* and its use as a dominant selectable marker. *Mol Cell Biol*, *6*: 2452-2461, 1986.
126. Thomas, J. H., Neff, N. F., and Botstein, D. Isolation and characterization of mutations in the beta-tubulin gene of *Saccharomyces cerevisiae*. *Genetics*, *111*: 715-734, 1985.
127. Nogales, E., Whittaker, M., Milligan, R. A., and Downing, K. H. High-resolution model of the microtubule. *Cell*, *96*: 79-88., 1999.
128. Jordan, M. A. and Wilson, L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer*, *4*: 253-265, 2004.
129. Nettles, J. H., Li, H., Cornett, B., Krahn, J. M., Snyder, J. P., and Downing, K. H. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. *Science*, *305*: 866-869, 2004.
130. Martello, L. A., Verdier-Pinard, P., Shen, H.-J., He, L., Torres, K., Orr, G. A., and Horwitz, S. B. Elevated Levels of Microtubule Destabilizing Factors in a Taxol-resistant/dependent A549 Cell Line with an {alpha}-Tubulin Mutation. *Cancer Res*, *63*: 1207-1213, 2003.
131. Hua, X. H., Genini, D., Gussio, R., Tawatao, R., Shih, H., Kipps, T. J., Carson, D. A., and Leoni, L. M. Biochemical genetic analysis of indanocine resistance in human leukemia. *Cancer Res*, *61*: 7248-7254, 2001.
132. Leoni, L. M., Hamel, E., Genini, D., Shih, H., Carrera, C. J., Cottam, H. B., and Carson, D. A. Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. *J Natl Cancer Inst*, *92*: 217-224, 2000.
133. Johnson, I. S., Wright, H. F., Svoboda, G. H., and Vlantis, J. Antitumor principles derived from *Vinca rosea* Linn. I. Vincalokoblastine and leurosine. *Cancer Res*, *20*: 1016-1022, 1960.
134. Cutts, J. H., Beer, C. T., and Noble, R. L. Biological properties of Vincalokoblastine, an alkaloid in *Vinca rosea* Linn, with reference to its antitumor action. *Cancer Res*, *20*: 1023-1031, 1960.
135. Zhou, J. and Giannakakou, P. Targeting microtubules for cancer chemotherapy. *Curr. Med. Chem.-Anti-Cancer Agents*, *5*: 65-71, 2005.
136. Kavallaris, M., Tait, A. S., Walsh, B. J., He, L., Horwitz, S. B., Norris, M. D., and Haber, M. Multiple microtubule alterations are associated with *Vinca* alkaloid resistance in human leukemia cells. *Cancer Research*, *61*: 5803-5809, 2001.
137. Poruchynsky, M. S., Kim, J. H., Nogales, E., Annable, T., Loganzo, F., Greenberger, L. M., Sackett, D. L., and Fojo, T. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. *Biochemistry*, *43*: 13944-13954, 2004.

138. Loganzo, F., Hari, M., Annable, T., Tan, X., Morilla, D. B., Musto, S., Zask, A., Kaplan, J., Minnick, A. A., Jr., May, M. K., Ayrál-Kaloustian, S., Poruchynsky, M. S., Fojo, T., and Greenberger, L. M. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. *Mol Cancer Ther*, 3: 1319-1327, 2004.
139. Sampath, D., Discafani, C. M., Loganzo, F., Beyer, C., Liu, H., Tan, X., Musto, S., Annable, T., Gallagher, P., Rios, C., and Greenberger, L. M. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. *Mol Cancer Ther*, 2: 873-884, 2003.
140. Tinley, T. L., Randall-Hlubek, D. A., Leal, R. M., Jackson, E. M., Cessac, J. W., Quada, J. C., Jr., Hemscheidt, T. K., and Mooberry, S. L. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity. *Cancer Res*, 63: 3211-3220, 2003.
141. Zhou, J., Gupta, K., Yao, J., Ye, K., Panda, D., Giannakakou, P., and Joshi, H. C. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH₂-terminal kinase-mediated apoptosis in response to noscipine. *J Biol Chem*, 277: 14, 2002.
142. Giannakakou, P., Gussio, R., Nogales, E., Downing, K. H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K. C., and Fojo, T. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. *Proc Natl Acad Sci U S A*, 97: 2904-2909., 2000.
143. He, L., Yang, C.-P. H., and Horwitz, S. B. Mutations in β -tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. *Molecular Cancer Therapeutics*, 1: 3-10, 2001.
144. Mehdi, N., Lartigot, M., Loretan, J., Altman, K-H., Fabbro, D., and Wartmann, M. A single point mutation in Human β -tubulin isoform M40 is associated with Epothilone-A resistance in two KB-31 Epidermoid carcinoma cell Lines. *Proceedings of the American Association for Cancer Research*, 42: 920, 2001.
145. Verrills, N. M., Flemming, C. L., Liu, M., Ivery, M. T., Cobon, G. S., Norris, M. D., Haber, M., and Kavallaris, M. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. *Chem Biol*, 10: 597-607, 2003.
146. Soussi, T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. *Ann N Y Acad Sci*, 910: 121-137; discussion 137-129, 2000.
147. Momand, J., Wu, H. H., and Dasgupta, G. MDM2--master regulator of the p53 tumor suppressor protein. *Gene*, 242: 15-29, 2000.
148. Sherr, C. J. and Weber, J. D. The ARF/p53 pathway. *Curr Opin Genet Dev*, 10: 94-99, 2000.
149. Carr, A. M. Cell cycle. Piecing together the p53 puzzle. *Science*, 287: 1765-1766, 2000.
150. Appella, E. and Anderson, C. W. Signaling to p53: breaking the posttranslational modification code. *Pathol Biol (Paris)*, 48: 227-245, 2000.
151. Ashcroft, M., Kubbutat, M. H., and Vousden, K. H. Regulation of p53 function and stability by phosphorylation. *Mol Cell Biol*, 19: 1751-1758, 1999.
152. Giaccia, A. J. and Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. *Genes Dev*, 12: 2973-2983, 1998.

153. Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. *Neoplasia*, 2: 208-225, 2000.
154. Jimenez, G. S., Khan, S. H., Stommel, J. M., and Wahl, G. M. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. *Oncogene*, 18: 7656-7665., 1999.
155. Meek, D. W. Mechanisms of switching on p53: a role for covalent modification? *Oncogene*, 18: 7666-7675, 1999.
156. Bates, S. and Vousden, K. H. Mechanisms of p53-mediated apoptosis. *Cell Mol Life Sci*, 55: 28-37, 1999.
157. Sionov, R. V. and Haupt, Y. The cellular response to p53: the decision between life and death. *Oncogene*, 18: 6145-6157, 1999.
158. O'Brate, A. and Giannakakou, P. The importance of p53 location: nuclear or cytoplasmic zip code? *Drug Resist Updat*, 6: 313-322, 2003.
159. Giannakakou, P., Nakano, M., Nicolaou, K. C., O'Brate, A., Yu, J., Blagosklonny, M. V., Greber, U. F., and Fojo, T. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. *Proc Natl Acad Sci U S A*, 99: 10855-10860., 2002.
160. Nikolaev, A. Y., Li, M., Puskas, N., Qin, J., and Gu, W. Parc: a cytoplasmic anchor for p53. *Cell*, 112: 29-40, 2003.
161. Wadhwa, R., Takano, S., Robert, M., Yoshida, A., Nomura, H., Reddel, R. R., Mitsui, Y., and Kaul, S. C. Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. *J Biol Chem*, 273: 29586-29591, 1998.
162. Wadhwa, R., Yaguchi, T., Hasan, M. K., Mitsui, Y., Reddel, R. R., and Kaul, S. C. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. *Exp Cell Res*, 274: 246-253, 2002.
163. Zhao, L. Y. and Liao, D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. *J Virol*, 77: 13171-13181, 2003.
164. Mihara, M. and Moll, U. M. Detection of mitochondrial localization of p53. *Methods Mol Biol*, 234: 203-209, 2003.
165. Charlot, J. F., Pretet, J. L., Haughey, C., and Mouglin, C. Mitochondrial translocation of p53 and mitochondrial membrane potential ($\Delta\Psi_m$) dissipation are early events in staurosporine-induced apoptosis of wild type and mutated p53 epithelial cells. *Apoptosis*, 9: 333-343, 2004.
166. Jordan, M. A. and Wilson, L. Use of drugs to study role of microtubule assembly dynamics in living cells. *Methods Enzymol*, 298: 252-276, 1998.
167. Derry, W. B., Wilson, L., and Jordan, M. A. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism. *Cancer Res*, 58: 1177-1184., 1998.
168. Ngan, V. K., Bellman, K., Panda, D., Hill, B. T., Jordan, M. A., and Wilson, L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. *Cancer Res*, 60: 5045-5051., 2000.
169. Jordan, M. A., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. *Proc Natl Acad Sci U S A*, 90: 9552-9556., 1993.

170. Neumann, T., Kirschstein, S. O., Camacho Gomez, J. A., Kittler, L., and Unger, E. Determination of the net exchange rate of tubulin dimer in steady-state microtubules by fluorescence correlation spectroscopy. *Biol Chem*, 382: 387-391., 2001.
171. Yvon, A. M., Wadsworth, P., and Jordan, M. A. Taxol suppresses dynamics of individual microtubules in living human tumor cells. *Mol Biol Cell*, 10: 947-959., 1999.
172. Torres, K. and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. *Cancer Res*, 58: 3620-3626., 1998.
173. Giannakakou, P., Poy, G., Zhan, Z., Knutsen, T., Blagosklonny, M. V., and Fojo, T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. *Oncogene*, 19: 3078-3085., 2000.
174. Woods, D. B. and Vousden, K. H. Regulation of p53 function. *Exp Cell Res*, 264: 56-66., 2001.
175. White, M. K. and McCubrey, J. A. Suppression of apoptosis: role in cell growth and neoplasia. *Leukemia*, 15: 1011-1021., 2001.
176. Vousden, K. H. p53: death star. *Cell*, 103: 691-694., 2000.
177. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., and Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. *Mol Cell*, 7: 673-682., 2001.
178. Nakano, K. and Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. *Mol Cell*, 7: 683-694., 2001.
179. Margolis, R. L. and Wilson, L. Microtubule treadmill: what goes around comes around. *Bioessays*, 20: 830-836., 1998.
180. Mitchison, T. and Kirschner, M. Dynamic instability of microtubule growth. *Nature*, 312: 237-242., 1984.
181. Rodionov, V., Nadezhdina, E., and Borisy, G. Centrosomal control of microtubule dynamics. *Proc Natl Acad Sci U S A*, 96: 115-120., 1999.
182. Mimori-Kiyosue, Y. and Tsukita, S. Where is APC going? *J Cell Biol*, 154: 1105-1110., 2001.
183. Ryan, K. M., Phillips, A. C., and Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. *Curr Opin Cell Biol*, 13: 332-337., 2001.
184. Crown, J. and O'Leary, M. The taxanes: an update. *Lancet*, 355: 1176-1178., 2000.
185. Zhu, H., Chang, B. D., Uchiumi, T., and Roninson, I. B. Identification of promoter elements responsible for transcriptional inhibition of polo-like kinase 1 and topoisomerase IIalpha genes by p21(WAF1/CIP1/SDI1). *Cell Cycle*, 1: 59-66, 2002.
186. Stewart, Z. A., Tang, L. J., and Pietsenpol, J. A. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. *Oncogene*, 20: 113-124., 2001.
187. Brown, J. M. and Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. *Nat Rev Cancer*, 4: 437-447, 2004.
188. Comerford, K. M., Wallace, T. J., Karhausen, J., Louis, N. A., Montalto, M. C., and Colgan, S. P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. *Cancer Res*, 62: 3387-3394, 2002.

189. Semenza, G. L. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer*, 3: 721-732, 2003.
190. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., and Simons, J. W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. *Cancer Res*, 59: 5830-5835., 1999.
191. Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., and Harris, A. L. The expression and distribution of the hypoxia-inducible factors HIF- 1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. *Am J Pathol*, 157: 411-421., 2000.
192. Escuin, D., Simons, J. W., and Giannakakou, P. Exploitation of the HIF Axis for Cancer Therapy. *Cancer Biol Ther*, 3: 608-611, 2004.
193. Rapisarda, A., Uranchimeg, B., Scudiero, D. A., Selby, M., Sausville, E. A., Shoemaker, R. H., and Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. *Cancer Res*, 62: 4316-4324., 2002.
194. Gradin, K., McGuire, J., Wenger, R. H., Kvietikova, I., fhitelaw, M. L., Toftgard, R., Tora, L., Gassmann, M., and Poellinger, L. Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. *Mol Cell Biol*, 16: 5221-5231, 1996.
195. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J., and Michiels, C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. *FEBS Lett*, 460: 251-256., 1999.
196. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1alpha -degradative Pathway. *J Biol Chem*, 277: 29936-29944., 2002.
197. Mabjeesh, N. J., Post, D. E., Willard, M. T., Kaur, B., Van Meir, E. G., Simons, J. W., and Zhong, H. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. *Cancer Res*, 62: 2478-2482., 2002.
198. Chun, Y. S., Yeo, E. J., Choi, E., Teng, C. M., Bae, J. M., Kim, M. S., and Park, J. W. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. *Biochem Pharmacol*, 61: 947-954, 2001.
199. Hsu, H. K., Juan, S. H., Ho, P. Y., Liang, Y. C., Lin, C. H., Teng, C. M., and Lee, W. S. YC-1 inhibits proliferation of human vascular endothelial cells through a cyclic GMP-independent pathway. *Biochem Pharmacol*, 66: 263-271, 2003.
200. Yeo, E. J., Chun, Y. S., Cho, Y. S., Kim, J., Lee, J. C., Kim, M. S., and Park, J. W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. *J Natl Cancer Inst*, 95: 516-525, 2003.
201. Jones, M. K., Szabo, I. L., Kawanaka, H., Husain, S. S., and Tarnawski, A. S. von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. *Faseb J*, 16: 264-266, 2002.
202. Palayoor, S. T., Tofilon, P. J., and Coleman, C. N. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. *Clin Cancer Res*, 9: 3150-3157, 2003.

203. Sun, X., Kanwar, J. R., Leung, E., Lehnert, K., Wang, D., and Krissansen, G. W. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy. *Gene Ther*, 8: 638-645, 2001.
204. Post, D. E. and Van Meir, E. G. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. *Oncogene*, 22: 2065-2072, 2003.
205. Greco, O., Marples, B., Joiner, M. C., and Scott, S. D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. *J Cell Physiol*, 197: 312-325, 2003.
206. Fulci, G. and Chiocca, E. A. Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. *Front Biosci*, 8: e346-360, 2003.
207. Fotsis, T., Zhang, Y., Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., and Schweigerer, L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. *Nature*, 368: 237-239., 1994.
208. Wassberg, E. Angiostatic treatment of neuroblastoma. *Ups J Med Sci*, 104: 1-24, 1999.
209. Sweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., and Sledge, G. W., Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. *Cancer Res*, 61: 3369-3372., 2001.
210. Kinuya, S., Kawashima, A., Yokoyama, K., Kudo, M., Kasahara, Y., Watanabe, N., Shuke, N., Bunko, H., Michigishi, T., and Tonami, N. Anti-angiogenic therapy and radioimmunotherapy in colon cancer xenografts. *Eur J Nucl Med*, 28: 1306-1312, 2001.
211. Huober, J. B., Nakamura, S., Meyn, R., Roth, J. A., and Mukhopadhyay, T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small- cell lung cancer. *Int J Radiat Oncol Biol Phys*, 48: 1127-1137., 2000.
212. Klauber, N., Parangi, S., Flynn, E., Hamel, E., and D'Amato, R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. *Cancer Res*, 57: 81-86., 1997.
213. Josefsson, E. and Tarkowski, A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. *Arthritis Rheum*, 40: 154-163, 1997.
214. Liehr, J. G., Fang, W. F., Sirbasku, D. A., and Ari-Ulubelen, A. Carcinogenicity of catechol estrogens in Syrian hamsters. *J Steroid Biochem*, 24: 353-356., 1986.
215. Rajan, R., Reddy, V. V., Reichle, F., David, J. S., and Daly, M. J. Effects of catechol estrogen methyl ethers on lipid metabolism in prepubertal rats. *Steroids*, 43: 499-507, 1984.
216. Yue, T. L., Wang, X., Loudon, C. S., Gupta, S., Pillarisetti, K., Gu, J. L., Hart, T. K., Lysko, P. G., and Feuerstein, G. Z. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. *Mol Pharmacol*, 51: 951-962., 1997.

217. Cushman, M., He, H. M., Katzenellenbogen, J. A., Lin, C. M., and Hamel, E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. *J Med Chem*, *38*: 2041-2049., 1995.
218. Verdier-Pinard, P., Wang, Z., Mohanakrishnan, A. K., Cushman, M., and Hamel, E. A steroid derivative with paclitaxel-like effects on tubulin polymerization. *Mol Pharmacol*, *57*: 568-575., 2000.
219. Aizu-Yokota, E., Susaki, A., and Sato, Y. Natural estrogens induce modulation of microtubules in Chinese hamster V79 cells in culture. *Cancer Res*, *55*: 1863-1868., 1995.
220. Lottering, M. L., de Kock, M., Viljoen, T. C., Grobler, C. J., and Seegers, J. C. 17beta-Estradiol metabolites affect some regulators of the MCF-7 cell cycle. *Cancer Lett*, *110*: 181-186, 1996.
221. Hayden, J. H., Bowser, S. S., and Rieder, C. L. Kinetochores capture astral microtubules during chromosome attachment to the mitotic spindle: direct visualization in live newt lung cells. *J Cell Biol*, *111*: 1039-1045, 1990.
222. Rusan, N. M., Fagerstrom, C. J., Yvon, A. M., and Wadsworth, P. Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin. *Mol Biol Cell*, *12*: 971-980, 2001.
223. Zhai, Y., Kronebusch, P. J., Simon, P. M., and Borisy, G. G. Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. *J Cell Biol*, *135*: 201-214, 1996.
224. Wang, X. M., Peloquin, J. G., Zhai, Y., Bulinski, J. C., and Borisy, G. G. Removal of MAP4 from microtubules in vivo produces no observable phenotype at the cellular level. *J Cell Biol*, *132*: 345-357, 1996.
225. Checchi, P. M., Nettles, J. H., Zhou, J., Snyder, J. P., and Joshi, H. C. Microtubule-interacting drugs for cancer treatment. *Trends Pharmacol Sci*, *24*: 361-365, 2003.
226. Altieri, D. C. Validating survivin as a cancer therapeutic target. *Nat Rev Cancer*, *3*: 46-54, 2003.
227. Zhou, J., Yao, J., and Joshi, H. C. Attachment and tension in the spindle assembly checkpoint. *J Cell Sci*, *115*: 3547-3555, 2002.
228. Ling, X., Bernacki, R. J., Brattain, M. G., and Li, F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. *J Biol Chem*, *279*: 15196-15203, 2004.
229. Blagosklonny, M. V. and Fojo, T. Molecular effects of paclitaxel: myths and reality (a critical review). *Int J Cancer*, *83*: 151-156, 1999.
230. O'Connor, D. S., Wall, N. R., Porter, A. C., and Altieri, D. C. A p34(cdc2) survival checkpoint in cancer. *Cancer Cell*, *2*: 43-54, 2002.
231. Eisenhauer, E. A. and Vermorken, J. B. The taxoids. Comparative clinical pharmacology and therapeutic potential. *Drugs*, *55*: 5-30, 1998.
232. Long, B. H., Carboni, J. M., Wasserman, A. J., Cornell, L. A., Casazza, A. M., Jensen, P. R., Lindel, T., Fenical, W., and Fairchild, C. R. Eleutherobin, a novel

- cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). *Cancer Res*, 58: 1111-1115, 1998.
233. Mooberry, S. L., Tien, G., Hernandez, A. H., Plubrukarn, A., and Davidson, B. S. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. *Cancer Res*, 59: 653-660., 1999.
 234. Hood, K. A., West, L. M., Rouwe, B., Northcote, P. T., Berridge, M. V., Wakefield, S. J., and Miller, J. H. Peloruside A, a novel antimetabolic agent with paclitaxel-like microtubule-stabilizing activity. *Cancer Res*, 62: 3356-3360, 2002.
 235. Kowalski, R. J., Giannakakou, P., and Hamel, E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). *J Biol Chem*, 272: 2534-2541, 1997.
 236. Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., and Hamel, E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. *Mol Pharmacol*, 52: 613-622, 1997.
 237. Hamel, E., Sackett, D. L., Vourloumis, D., and Nicolaou, K. C. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. *Biochemistry*, 38: 5490-5498., 1999.
 238. Andreu, J. M., Perez-Ramirez, B., Gorbunoff, M. J., Ayala, D., and Timasheff, S. N. Role of the colchicine ring A and its methoxy groups in the binding to tubulin and microtubule inhibition. *Biochemistry*, 37: 8356-8368, 1998.
 239. Pryor, D. E., O'Brate, A., Bilcer, G., Diaz, J. F., Wang, Y., Kabaki, M., Jung, M. K., Andreu, J. M., Ghosh, A. K., Giannakakou, P., and Hamel, E. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. *Biochemistry*, 41: 9109-9115, 2002.
 240. Andreu, J. M. and Barasoain, I. The interaction of baccatin III with the taxol binding site of microtubules determined by a homogeneous assay with fluorescent taxoid. *Biochemistry*, 40: 11975-11984, 2001.
 241. Diaz, J. F., Strobe, R., Engelborghs, Y., Souto, A. A., and Andreu, J. M. Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site. *J Biol Chem*, 275: 26265-26276, 2000.
 242. Lowe, J., Li, H., Downing, K. H., and Nogales, E. Refined structure of alpha beta-tubulin at 3.5 Å resolution. *J Mol Biol*, 313: 1045-1057, 2001.
 243. Martello, L. A., McDaid, H. M., Regl, D. L., Yang, C. P., Meng, D., Pettus, T. R., Kaufman, M. D., Arimoto, H., Danishefsky, S. J., Smith, A. B., 3rd, and Horwitz, S. B. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. *Clin Cancer Res*, 6: 1978-1987, 2000.
 244. Zhou, J., Panda, D., Landen, J. W., Wilson, L., and Joshi, H. C. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. *J Biol Chem*, 277: 17200-17208, 2002.

245. Ghosh, A. K., Wang, Y., and Kim, J. T. Total synthesis of microtubule-stabilizing agent (-)-laulimalide. *J Org Chem*, *66*: 8973-8982, 2001.
246. Hamel, E. and Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. *Biochemistry*, *23*: 4173-4184, 1984.
247. Nicolaou, K. C., Finlay, M. R., Ninkovic, S., King, N. P., He, Y., Li, T., Sarabia, F., and Vourloumis, D. Synthesis and biological properties of C12,13-cyclopropyl-epothilone A and related epothilones. *Chem Biol*, *5*: 365-372, 1998.
248. Nicolaou, K. C., Yang, Z., Shi, G., Gunzner, J. L., Agrios, K. A., and Gartner, P. Total synthesis of brevetoxin A. *Nature*, *392*: 264-269, 1998.
249. Diaz, J. F. and Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. *Biochemistry*, *32*: 2747-2755, 1993.
250. Wang, Y., O'Brate, A., Zhou, W., and Giannakakou, P. Resistance to Microtubule-Stabilizing Drugs Involves two Genetic Events: Mutation in β -tubulin in one allele Followed by Loss of the second allele., Submitted.
251. Wang, Y., Zhou, W., Giannakakou, P. Resistance to Microtubule-Stabilizing Drugs Requires two Genetic Events: Mutation in β -tubulin in one parental allele Followed by Mutation/Loss of the second allele. *Proc. Amer. Assoc. Cancer Res.* (2nd ed.), *44*, 2003.
252. Esteller, M., Fraga, M. F., Guo, M., Garcia-Foncillas, J., Hedenfalk, I., Godwin, A. K., Trojan, J., Vaurs-Barriere, C., Bignon, Y. J., Ramus, S., Benitez, J., Caldes, T., Akiyama, Y., Yuasa, Y., Launonen, V., Canal, M. J., Rodriguez, R., Capella, G., Peinado, M. A., Borg, A., Aaltonen, L. A., Ponder, B. A., Baylin, S. B., and Herman, J. G. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. *Hum Mol Genet*, *10*: 3001-3007, 2001.
253. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., White, R., and Vogelstein, B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science*, *244*: 217-221, 1989.
254. Thiagalingam, S., Laken, S., Willson, J. K., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., and Lengauer, C. Mechanisms underlying losses of heterozygosity in human colorectal cancers. *Proc Natl Acad Sci U S A*, *98*: 2698-2702, 2001.
255. Arias-Pulido, H., Joste, N., and Wheeler, C. M. Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype. *Genes Chromosomes Cancer*, *40*: 277-284, 2004.
256. Loeb, L. A., Loeb, K. R., and Anderson, J. P. Multiple mutations and cancer. *Proc Natl Acad Sci U S A*, *100*: 776-781, 2003.
257. Chatterjee, A., Pulido, H. A., Koul, S., Beleno, N., Perilla, A., Posso, H., Manusukhani, M., and Murty, V. V. S. Mapping the Sites of Putative Tumor Suppressor Genes at 6p25 and 6p21.3 in Cervical Carcinoma: Occurrence of Allelic Deletions in Precancerous Lesions. *Cancer Res*, *61*: 2119-2123, 2001.
258. McEvoy, C. R., Morley, A. A., and Firgaira, F. A. Evidence for whole chromosome 6 loss and duplication of the remaining chromosome in acute lymphoblastic leukemia. *Genes Chromosomes Cancer*, *37*: 321-325, 2003.

259. Miyai, K., Furugen, Y., Matsumoto, T., Iwabuchi, K., Hirose, S., Kinoshita, K., and Fujii, H. Loss of heterozygosity analysis in uterine cervical adenocarcinoma. *Gynecol Oncol*, *94*: 115-120, 2004.
260. Rodriguez, T., Mendez, R., Roberts, C. H., Ruiz-Cabello, F., Dodi, I. A., Lopez Nevot, M. A., Paco, L., Maleno, I., Marsh, S. G., Pawelec, G., and Garrido, F. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. *Cancer Immunol Immunother*, *54*: 141-148, 2005.
261. Hurst, C. D., Fiegler, H., Carr, P., Williams, S., Carter, N. P., and Knowles, M. A. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. *Oncogene*, *23*: 2250-2263, 2004.
262. Adjei, A. A. Blocking oncogenic Ras signaling for cancer therapy. *J Natl Cancer Inst*, *93*: 1062-1074, 2001.
263. Brunner, T. B., Hahn, S. M., Gupta, A. K., Muschel, R. J., McKenna, W. G., and Bernhard, E. J. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. *Cancer Res*, *63*: 5656-5668, 2003.
264. Hahn, S. M., Bernhard, E., and McKenna, W. G. Farnesyltransferase inhibitors. *Semin Oncol*, *28*: 86-93, 2001.
265. McCormick, F. Ras-related proteins in signal transduction and growth control. *Mol Reprod Dev*, *42*: 500-506, 1995.
266. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and Der, C. J. Farnesyl modification of Kirsten-ras exon 4B protein is essential for transformation. *Proc Natl Acad Sci U S A*, *87*: 3042-3046, 1990.
267. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. *Proc Natl Acad Sci U S A*, *89*: 6403-6407, 1992.
268. Barbacid, M. ras genes. *Annu Rev Biochem*, *56*: 779-827, 1987.
269. Bos, J. L. ras oncogenes in human cancer: a review. *Cancer Res*, *49*: 4682-4689, 1989.
270. Li, T. and Sparano, J. A. Inhibiting Ras signaling in the therapy of breast cancer. *Clin Breast Cancer*, *3*: 405-416; discussion 417-420, 2003.
271. End, D. W., Smets, G., Todd, A. V., Applegate, T. L., Fuery, C. J., Angibaud, P., Venet, M., Sanz, G., Poignet, H., Skrzat, S., Devine, A., Wouters, W., and Bowden, C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. *Cancer Res*, *61*: 131-137, 2001.
272. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. *Cancer Res*, *55*: 5310-5314, 1995.
273. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. *Cancer Res*, *55*: 5302-5309, 1995.

274. Moasser, M. M. and Rosen, N. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. *Breast Cancer Res Treat*, *73*: 135-144, 2002.
275. Nogales, E. Structural insights into microtubule function. *Annu Rev Biochem*, *69*: 277-302, 2000.
276. Drukman, S. and Kavallaris, M. Microtubule alterations and resistance to tubulin-binding agents (review). *Int J Oncol*, *21*: 621-628, 2002.
277. Wartmann, M. and Altmann, K. H. The biology and medicinal chemistry of epothilones. *Curr Med Chem Anti-Canc Agents*, *2*: 123-148, 2002.
278. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D. S., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. *Proc Natl Acad Sci U S A*, *95*: 1369-1374, 1998.
279. Sun, J., Blaskovich, M. A., Knowles, D., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., and Sebti, S. M. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. *Cancer Res*, *59*: 4919-4926, 1999.
280. Shi, B., Yaremko, B., Hajian, G., Terracina, G., Bishop, W. R., Liu, M., and Nielsen, L. L. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. *Cancer Chemother Pharmacol*, *46*: 387-393, 2000.
281. Khuri, F. R., Glisson, B. S., Kim, E. S., Statkevich, P., Thall, P. F., Meyers, M. L., Herbst, R. S., Munden, R. F., Tendler, C., Zhu, Y., Bangert, S., Thompson, E., Lu, C., Wang, X. M., Shin, D. M., Kies, M. S., Papadimitrakopoulou, V., Fossella, F. V., Kirschmeier, P., Bishop, W. R., and Hong, W. K. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. *Clin Cancer Res*, *10*: 2968-2976, 2004.
282. Crespo, N. C., Ohkanda, J., Yen, T. J., Hamilton, A. D., and Sebti, S. M. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. *J Biol Chem*, *276*: 16161-16167, 2001.
283. Crespo, N. C., Delarue, F., Ohkanda, J., Carrico, D., Hamilton, A. D., and Sebti, S. M. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. *Cell Death Differ*, *9*: 702-709, 2002.
284. Ashar, H. R., James, L., Gray, K., Carr, D., Black, S., Armstrong, L., Bishop, W. R., and Kirschmeier, P. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. *J Biol Chem*, *275*: 30451-30457, 2000.
285. Taveras, A. G., Kirschmeier, P., and Baum, C. M. Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations. *Curr Top Med Chem*, *3*: 1103-1114, 2003.
286. Marcus, A. I., Zhou, J., O'Brate, A., Hamel, E., Wong, J., Nivens, M., El-Naggar, A., Yao, T. P., Khuri, F. R., and Giannakakou, P. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin

- acetylation and requires a functional tubulin deacetylase. *Cancer Res*, *65*: 3883-3893, 2005.
287. Giannakakou, P., Villalba, L., Li, H., Poruchynsky, M., and Fojo, T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. *Int J Cancer*, *75*: 57-63, 1998.
 288. Kamath, K. and Jordan, M. A. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. *Cancer Res*, *63*: 6026-6031, 2003.
 289. Marcus, A. I., O'Brate, A., Buey, R., Zhou, J., Thomas, S., Diaz, F., Giannakakou, P. Farnesyl transferase inhibitors reverse resistance to taxanes. *PNAS*, *submitted*, 2005.
 290. Dy, G. K., Bruzek, L. M., Croghan, G. A., Mandrekar, S., Erlichman, C., Peethambaram, P., Pitot, H. C., Hanson, L. J., Reid, J. M., Furth, A., Cheng, S., Martell, R. E., Kaufmann, S. H., and Adjei, A. A. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. *Clin Cancer Res*, *11*: 1877-1883, 2005.
 291. Zhou, J., O'Brate, A., Zelnak, A., and Giannakakou, P. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol. *Cancer Res*, *64*: 8708-8714, 2004.
 292. Diaz, J. F., Menendez, M., and Andreu, J. M. Thermodynamics of ligand-induced assembly of tubulin. *Biochemistry*, *32*: 10067-10077, 1993.
 293. Parness, J. and Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. *J Cell Biol*, *91*: 479-487, 1981.
 294. Caplow, M., Shanks, J., and Ruhlen, R. How taxol modulates microtubule disassembly. *J Biol Chem*, *269*: 23399-23402, 1994.
 295. Suzuki, N., Del Villar, K., and Tamanoi, F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. *Proc Natl Acad Sci U S A*, *95*: 10499-10504, 1998.
 296. Hussein, D. and Taylor, S. S. Farnesylation of Cennp-F is required for G2/M progression and degradation after mitosis. *J Cell Sci*, *115*: 3403-3414, 2002.
 297. Laezza, C., Wolff, J., and Bifulco, M. Identification of a 48-kDa prenylated protein that associates with microtubules as 2',3'-cyclic nucleotide 3'-phosphodiesterase in FRTL-5 cells. *FEBS Lett*, *413*: 260-264, 1997.
 298. Bifulco, M., Laezza, C., Stingo, S., and Wolff, J. 2',3'-Cyclic nucleotide 3'-phosphodiesterase: a membrane-bound, microtubule-associated protein and membrane anchor for tubulin. *Proc Natl Acad Sci U S A*, *99*: 1807-1812, 2002.
 299. Kawaguchi, Y., Kovacs, J. J., McLaurin, A., Vance, J. M., Ito, A., and Yao, T. P. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. *Cell*, *115*: 727-738, 2003.
 300. Mayhew, C. N., Sumpter, R., Inayat, M., Cibull, M., Phillips, J. D., Elford, H. L., and Gallicchio, V. S. Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease. *Antiviral Res*, *65*: 13-22, 2005.

301. Kollef, M. H. Gram-negative bacterial resistance: evolving patterns and treatment paradigms. *Clin Infect Dis*, *40 Suppl 2*: S85-88, 2005.
302. Waterer, G. W. Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. *Curr Opin Infect Dis*, *18*: 157-163, 2005.
303. DiazGranados, C. A. and Jernigan, J. A. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. *J Infect Dis*, *191*: 588-595, 2005.
304. Palazzo, I. C., Araujo, M. L., and Darini, A. L. First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil. *J Clin Microbiol*, *43*: 179-185, 2005.